

Acute Flaccid Paralysis (AFP): Surveillance Standard for Certification

Situation Analysis in the European Region

November 1999



In addition to finding poliovirus if it is circulating, the BIG Question answered by *AFP surveillance* is:



How can we be certain that there is no wild poliovirus in a country which reports 'zero' cases of polio?




PARALYTIC

NON-PARALYTIC

**AFP
SURVEILLANCE
raises the "iceberg"**

New Infections

"Reinfections"



HOW?

AFP SURVEILLANCE **The Process**

Onset of paralysis

↓ **≤ 7 days of onset**

Detection & notification

↓ **≤ 14 days of onset**

Case investigation & specimen collection

→ **≤ 3 days of being sent**

Specimens arrive at national lab

↘ **≤ 28 days**

Primary culture results reported to EPI

Isolates sent to regional lab for intra-typic differentiation



Intra-typic differentiation results reported to EPI

↓ **≥ 60 days of onset**

Follow-up exam



Classification of case (≤ 12 weeks of onset)



WHAT?


AFP Case Definition

AFP:

Any case of flaccid paralysis of acute onset in a child aged less than 15 years of age;

Clinically suspected polio at any age





Estimates of GBS incidence rates per 100 000 children <15 years

- **Canada, USA:** **1.2** **by hospital diagnosis**
- **PAHO:** **0.91** **subset with neurologist review**
- **various:** **0.6-2.4** **total population**



AFP Surveillance Performance Indicators






System Sensitivity

 **Non-polio AFP rate in children < 15 years of age**
Objective: $\geq 1 / 100\ 000$

 **Geographic areas representative of population**
Objective: $\geq ALL$


AFP Surveillance Performance Indicators

Reporting and Investigation Operations


-  **Completeness: % of all expected AFP weekly reports received**
Objective: 90%
-  **Timeliness: % of all expected AFP weekly reports received by deadline**
Objective: 90%
-  **Investigation \leq 48 hours of report**
Objective: \geq 80%
-  **2 stools collected \leq 14 days of paralysis onset (\geq 24 hrs apart)**
Objective: \geq 80%
-  **Living patient with follow-up at 60 days for residual paralysis**
Objective: \geq 80%




Performance Indicators of AFP surveillance in the European Region of WHO: all reporting countries and recently endemic



Non-Polio AFP Rate by MECACAR Plus Country, 1999



Percent of AFP cases with 2 Faecal Specimens within 14 days, MECACAR Plus Countries, 1999



Calculation of Index of non-polio AFP among Member States conducting AFP surveillance in the European Region of WHO


Index = non-polio AFP incidence per 100 000
[maximum of 1.0]
x
proportion with 2 faecal specimens*
 ≤ 14 days of onset and ≥ 24 hours apart

For example: $0.8 \times 70\% = 0.56$
 $1.2 \times 80\% = 0.80$


**for non-endemic countries, at least one specimen within 14 days*




AFP Surveillance Index in the European Region of WHO: Non-endemic and Recently Endemic Countries 1997-1999 to date




AFP Surveillance Index by MECACARP Plus Country, 1999




AFP Surveillance Index, EUR Recently Endemic Countries, 1997-1999




AFP Surveillance Index, EUR Recently Endemic Countries, 1997-1999



Index rates of non-polio AFP among Member States conducting AFP surveillance in the European Region of WHO, 1998*




*index=(incidence [max 1.0] x proportion with faecal specimens); AFP includes facial paralysis for Russia; as of 29 Jul 1999.




+not all specimens tested in national laboratory




Index rates of non-polio AFP among Member States conducting AFP surveillance in the European Region of WHO, 1999*




*index=(incidence [max 1.0] x proportion with faecal specimens); as of 13 July 1999.



Index rates of non-polio AFP among Member States conducting AFP surveillance in the European Region of WHO, 1999*



*index=(incidence [max 1.0] x proportion with appropriate faecal specimens); as of 22 Nov 1999.



+not all specimens tested in national laboratory

